Henlius Denosumab Biosimilar Trial Enters Phase III

As Firm’s Shanghai Plant Has Received EU GMP Equivalence

 
• By Chloe Kent
  
Osteoporosis
The study will evaluate the impact of Henlius' candidate on bone mineral density. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin